Endocrine Abstracts

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

Neuroendocrine tumors (NETs) are uncommon neoplasms with increasing incidence and limited therapeutic options, wherein identification of new diagnostic/prognostic/therapeutic biomarkers is urgently required. Alterations in somatostatin (SST)/cortistatin (CORT) and ghrelin systems have been associated to development/progression of several cancers. Thus, we evaluated expression levels of SST/CORT/ghrelin system components in gastroenteropancreatic-neuroendocrine tumors (GEP-NETs...

Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms from the endocrine pancreas, whose incidence is recently rising. Unfortunately, an advanced stage is often found at diagnosis; thus, identification of new molecular diagnostic, prognostic, and therapeutic markers is required. Ghrelin and somatostatin/cortistatin systems are two multifunctional regulatory complexes widely distributed throughout multiple tissues, including the pancreas, where they exert diverse (pat...

Somatostatin is a pleiotropic neuropeptide that governs multiple biological targets, including tumor cell function, through a family of G protein-coupled receptors with 7-transmembrane domains (TMD), named sst1-5. However, we recently discovered sst5TMD4, an aberrantly spliced, truncated (only 4-TMDs) sst5-variant displaying unique molecular/functional features. sst5TM4 is overexpressed in various endocrine-related tumors exacerbating their malignant characteristics. Here, we ...

Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all intracranial tumors and comprise a varied type of neoplasms that, despite being rarely metastatic, can cause severe comorbidities and increased mortality related to the mass effects and hormonal hypersecretion. The high expression levels of somatostatin and dopamine receptors in these tumors has led to the use of somatostatin analogues (SSAs) and dopamine agonists (DAs) as pharmacological treatments....

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...